vTv Therapeutics (FRA:5VT0) Institutional Ownership: 12.21% (As of Jul. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:5VT0 vTv Therapeutics Inc FRA:5VT0
35 GF Score
Price €27.20
GF Value €6,512.78
View Full Analysis

What is vTv Therapeutics Institutional Ownership?

vTv Therapeutics FRA:5VT0 +0.74% 35 Institutional Ownership is 12.21% as of Jul. 16, 2026. GuruFocus rates FRA:5VT0 with a GF Score™ of 35/100 and a GF Value™ of €6,512.78.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, vTv Therapeutics's institutional ownership is 12.21%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, vTv Therapeutics's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, vTv Therapeutics's Float Percentage Of Total Shares Outstanding is 60.51%.

vTv Therapeutics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for vTv Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

vTv Therapeutics Institutional Ownership Chart

vTv Therapeutics Historical Data

The historical data trend for vTv Therapeutics can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 7.25 7.31 7.37 10.32 11.43 11.32 12.00 12.11 12.10 12.21
FRA:5VT0
35GF Score
vTv Therapeutics Inc FRA:5VT0
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

vTv Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 12.21% mean?
vTv Therapeutics (FRA:5VT0) has a Institutional Ownership of 12.21% as of Jul. 16, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on vTv Therapeutics and its competitors.
Is vTv Therapeutics' Institutional Ownership too high?
vTv Therapeutics' current Institutional Ownership is 12.21%. Overall, vTv Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does vTv Therapeutics' Institutional Ownership compare to SMNR and CNTB?
vTv Therapeutics' Institutional Ownership of 12.21% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on vTv Therapeutics and its competitors. vTv Therapeutics's current Institutional Ownership is 12.21%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is vTv Therapeutics stock overvalued right now?
vTv Therapeutics (FRA:5VT0) has a current Institutional Ownership of 12.21%. The stock's GF Value™ is €6,512.78, compared to a current price of €27.20 — trading 99.6% below its estimated fair value. The current Institutional Ownership is 12.21%. vTv Therapeutics' overall GF Score™ is 35/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For vTv Therapeutics (FRA:5VT0), the current Institutional Ownership is 12.21% as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is vTv Therapeutics (FRA:5VT0) Overvalued in 2026?

Based on GuruFocus' analysis, vTv Therapeutics stock appears to be undervalued. The current stock price of €27.20 is trading 99.6% below its estimated GF Value™ of €6,512.78.

Key valuation signals for FRA:5VT0:

  • Institutional Ownership: 12.21%
  • GF Value™: €6,512.78 vs. price of €27.20 (99.6% below fair value)
  • GF Score™: 35/100

No single metric tells the full story. See the FRA:5VT0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

vTv Therapeutics Business Description

Other Exchanges VTVT:USA
Address 3980 Premier Drive, Suite 110, High Point, NC, USA, 27265
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.
35GF Score

Get the complete analysis for FRA:5VT0

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€27.20
Price
€6,512.78
GF Value